玻璃体腔注射抗血管内皮生长因子治疗新生血管性年龄相关性黄斑变性后视力与残留视网膜液体的关联:系统评价与Meta分析
该系统评价与Meta分析纳入11项研究共3092只眼,评估抗VEGF治疗后残留视网膜下液(SRF)和视网膜内液(IRF)与视力预后的关联。结果显示残留SRF与末次观察时BCVA略好相关,但随机对照试验中无显著差异;残留IRF与BCVA较差及较基线改善更少相关。证据确定性低,结论受观察性研究数据、异质性和基线差异限制。
要点
- 残留SRF眼末次BCVA优于无SRF眼(WMD 3.1字母,95%CI 0.05-6.18),但RCT中无显著差异。
- 残留IRF眼末次BCVA较无IRF眼差(WMD -8.2字母,95%CI -11.79至-4.50,P<.001)。
- 残留IRF还与较基线BCVA改善更少相关,证据确定性低。
核心结论
- 残留SRF的存在与末次观察时略好的BCVA相关,但基线BCVA存在差异且该结论主要由1项研究驱动。
- 残留IRF的存在与末次观察时BCVA明显更差及较基线改善更少相关。
- 结论受纳入观察性研究数据、异质性和低确定性证据限制。
研究设计与样本
- 系统评价与Meta分析,检索2005年1月至2021年8月Ovid MEDLINE、Embase和Cochrane Library。
- 纳入报告nAMD患者玻璃体腔注射贝伐珠单抗、雷珠单抗、阿柏西普或布罗鲁珠单抗后末次观察时按残留SRF、IRF或任何视网膜液体分层视力的同行评议文章。
- 排除非比较性研究、少于10只眼的研究及报告其他抗VEGF药物的研究。
- 共纳入11项研究(6项随机临床试验),3092只眼。
- 采用Cochrane偏倚风险工具2和ROBINS-I评估偏倚风险,GRADE评估证据确定性。
主要发现
- 残留SRF眼末次BCVA优于无SRF眼(WMD 3.1字母,95%CI 0.05至6.18,P=.05;GRADE低确定性;6项研究;1931只眼)。
- 随机临床试验中残留SRF眼与无SRF眼末次BCVA相似(WMD 2.7字母,95%CI -2.40至7.84,P=.30;GRADE低确定性;3项研究;1406只眼)。
- 残留IRF眼末次BCVA差于无IRF眼(WMD -8.2字母,95%CI -11.79至-4.50,P<.001;GRADE低确定性;7项研究;2114只眼)。
关键数值与推荐
- 残留SRF与末次BCVA较好相关:WMD 3.1字母(95%CI 0.05至6.18,P=.05),GRADE低确定性。
- RCT中残留SRF与末次BCVA无显著差异:WMD 2.7字母(95%CI -2.40至7.84,P=.30),GRADE低确定性。
- 残留IRF与末次BCVA较差相关:WMD -8.2字母(95%CI -11.79至-4.50,P<.001),GRADE低确定性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 结论受纳入观察性研究数据限制。
- 结论受异质性限制。
- 结论受低确定性证据限制。
- 基线BCVA存在差异且SRF结论主要由1项研究驱动。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The association between residual subretinal fluid (SRF) and intraretinal fluid (IRF) and visual acuity following anti-vascular endothelial growth factor (VEGF) treatment is not well understood. OBJECTIVE: To examine the association of residual retinal fluid, SRF, and IRF with visual acuity following anti-VEGF treatment in patients with neovascular age-related macular degeneration (nAMD). DATA SOURCES: A systematic literature search was performed from January 2005 to August 2021 using Ovid MEDLINE, Embase, and the Cochrane Library. STUDY SELECTION: Peer-reviewed articles reporting on visual acuity stratified by the presence or absence of any residual SRF, IRF, or any retinal fluid at last study observation after intravitreal bevacizumab, ranibizumab, aflibercept, or brolucizumab in patients with nAMD were included. Studies that were noncomparative, included fewer than 10 eyes, or reported on other anti-VEGF agents were excluded. DATA EXTRACTION AND SYNTHESIS: Two independent reviewers conducted data extraction and synthesis. The Cochrane risk of bias tool 2 and ROBINS-I were used to assess risk of bias and GRADE evaluation was conducted to assess certainty of evidence. MAIN OUTCOMES AND MEASURES: Primary outcomes were BCVA at last study observation, change in BCVA from baseline, and retinal thickness at last study observation. RESULTS: In this systematic review and meta-analysis, 11 studies (6 randomized clinical trials [RCTs]) comprising 3092 eyes were included in our analysis. Across all included studies, the BCVA of eyes with residual SRF was better than eyes without SRF (weighted mean difference [WMD], 3.1 letter score; 95% CI, 0.05 to 6.18; P = .05; GRADE, low certainty of evidence; 6 studies; 1931 eyes) but similar in RCTs (WMD, 2.7 letter score; 95% CI, -2.40 to 7.84; P = .30; GRADE, low certainty of evidence; 3 studies; 1406 eyes). The BCVA of eyes with residual IRF was worse than that of eyes without IRF (WMD, -8.2 letter score; 95% CI, -11.79 to -4.50; P < .001; GRADE, low; 7 studies; 2114 eyes). CONCLUSIONS AND RELEVANCE: The findings suggest that the presence of residual SRF was associated with slightly better BCVA at last study observation; however, baseline differences in BCVA existed and this conclusion was primarily driven by 1 study. The presence of residual IRF was associated with substantially worse BCVA at last study observation and less improvement of BCVA from baseline. The conclusions are limited by the inclusion of data from observational studies, heterogeneity, and a low certainty of evidence.
引用
- Patil NS, Mihalache A, Dhoot AS, et al. Association Between Visual Acuity and Residual Retinal Fluid Following Intravitreal Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-analysis. JAMA Ophthalmol. 2022. PMID: 35551359. doi:10.1001/jamaophthalmol.2022.1357
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。